Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer

Inclusion Criteria: * Cytologically or histologically confirmed advanced or metastatic HCC. If no histological diagnosis, patient must have imaging studies compatible with HCC. * Age 18 years and above * ECOG performance status of 0 or 1 * Not a candidate for curative treatments (i.e., resection, transplantation) * Child-Pugh class A or B7 liver function * Measurable disease as defined by RECIST 1.1 * Patients who received prior local therapy (e.g., TACE) are eligible. * Documented virology status of hepatitis, as confirmed by screening HBsAg, anti-HBc, and/or anti-HCV * Life expectancy\> 3 months * For women who are not postmenopausal (12 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of contraception. For men: agreement to use a barrier method of contraception during the treatment period * Hematologic, Biochemical, and Organ Function within 7 days prior to Cycle 1 Day 1: Granulocyte count \> 1500/mm3, Platelet count \> 75,000/ mm3, Hemoglobin \> 8 g/dL; Total bilirubin \< 2.0; Albumin \> 2.8g/dl; AST (SGOT) and ALT (SGPT) \< 5 x ULN; Serum creatinine\< 1.5 x ULN * Cohort 1 (with sorafenib): No previous systemic therapy including sorafenib or chemotherapy treatment. Previous TACE and local treatments are permitted. * Cohort 2 (on progression of sorafenib): Patients who have received prior sorafenib therapy for at least 4 weeks and has confirmation of disease progression on CT/MRI. Prior surgery or local …